title: High expression of miR-9 in CD133+glioblastoma cells in chemoresistance to temozolomide.
abstract: Glioblastoma Multiforme (GBM), a uniformly lethal stage IV astrocytoma, is currently treated with a combination of surgical and radiation therapy as well as Temozolomide (TMZ) chemotherapy. Resistance to TMZ is rapidly acquired by GBM cells and overcoming this resistance has been an area of signi?cant research. GBM 'cancer stem cells' (CSC) also known as 'cancer initiating cells' are often positively selected by CD133 expression and TMZ resistance. In this project, we selected GBM CSC from two cell lines based on CD133 expression. CD133+and CD133-GBM cells showed comparable cell cycle status. The expression of genes within the Sonic Hedgehog Signaling pathway, PTCH1 (SHH receptor/basal signaling repressor) and Gli1 (effector transcription factor) were increased. The recent literature indicated a decreased in PTCH expression by miRNA and this was independent of SHH expression. We analyzed 5 potential PTCH-targeting miRNA and identi?ed an increase in miRNA-9-2. The CD133+cells showed an increase in the Multiple Drug Resistance 1 gene (MDR1). Knockdown of Gli1 and MDR1 with siRNA enhanced TMZ induced cell death. Taken together, these studies show CD133+GBM CSCs expressed greater levels of miR-9 and activation of the SHH/PTCH1/MDR1 axis. This axis has been shown to impart TMZ resistance. In the case of the CD133+cells, the resistance is not acquires but seems to be inherent. Identi?cation of this pathway as well as the identi?cation of miR-9 may allow for the development of miRNA-targeted approach to Cancer Stem Cell therapy in GBM.
authors.affiliation: New Jersey Medical School, Rutgers, Newark Campus, NJ; Graduate School of Biomedical Science, Rutgers School of Biomedical Health Sciences, Newark Campus, NJ.
authors.forename: Jessian L
authors.initials: JL
authors.lastname: Munoz
authors.affiliation: University of Puerto Rico, Chemistry Department, Cayey, Puerto Rico.
authors.forename: Vivian
authors.initials: V
authors.lastname: Rodriguez-Cruz
authors.affiliation: New Jersey Medical School, Rutgers, Newark Campus, NJ; Graduate School of Biomedical Science, Rutgers School of Biomedical Health Sciences, Newark Campus, NJ.
authors.forename: Pranela
authors.initials: P
authors.lastname: Rameshwar
keywords: CD133+ cells; Cancer stem cell; Glioblastoma; Temozolomide; miRNA-9